CytomX Q2 2025 cash $158.1M; positive CX-2051 Phase 1 data; $100M offering closed

CytomX Therapeutics, Inc.

Revenue $18.7M in Q2 2025 vs $25.1M in Q2 2024; operating expenses fell to $19.9M from $33.6M.
Cash, equivalents and investments $158.1M at June 30, 2025, up from $79.9M on March 31, 2025; cash runway to Q2 2027.
Positive interim data from CX-2051 Phase 1 in advanced colorectal cancer; dose expansions initiated at 7.2, 8.6, 10 mg/kg Q3W.
CX-2051 Phase 1 data update on ~70 patients by Q1 2026; Phase 2 study in late-line CRC expected in 1H 2026.
Completed $100M underwritten offering, net proceeds $93.4M; CX-801 plus KEYTRUDA dose escalation started for advanced melanoma.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.